The aim of the present study was to investigate the activities of clindamycin, imipenem, metronidazole, and piperacillin-tazobactam against 12 Bacteroides fragilis isolates (resistant and susceptible strains) by kill kinetics over 24 h. In contrast to the other antimicrobial agents, clindamycin did not affect strains with MICs of >8.0 g/ml. For those strains with MICs of <8.0 g/ml, all employed antibiotics except clindamycin showed nearly bactericidal activity. Metronidazole proved to be the most active antimicrobial agent.
clindamycin (Sigma Chemical Co.), imipenem (Merck & Co., Inc., West Point, PA), metronidazole (Sigma Chemical Co.), and piperacillin (Sigma Chemical Co.)-tazobactam (Otsuka Chemical Co. Ltd., Osaka, Japan) were assessed using 0.5ϫ, 1ϫ, 2ϫ, or 4ϫ MIC. In the case of strains with MICs of Ͼ8.0 g/ml, concentrations at 0.5ϫ, 1ϫ, 2ϫ, or 4ϫ maximum concentrations of drug in serum (C max s) were employed. The indicated concentrations were used as C max s: clindamycin, 16 g/ml (8); imipenem, 32 g/ml (22); metronidazole, 16 g/ml (11, 13, 15) ; piperacillin, 60 g/ml (2); and tazobactam, 25 g/ml (12, 14, 19 ).
An assay with antibiotic-free growth control was performed parallel to each experiment. The final inocula contained approximately 1.5 ϫ 10 7 CFU/ml. At 0, 2, 4, 6, 12, and 24 h after incubation at 37°C, aliquots were plated on the supplemented Columbia agar. CFU were counted after 48 h of incubation. The detection limit was 10 2 CFU/ml. All experiments were carried out in an anaerobic chamber (Heraeus, Hanau, Germany) containing 5% H 2 , 15% CO 2 , and 80% N 2 .
For all strains and their respective antimicrobial agents, the mean value and standard deviation were calculated. Statistical analysis was done with SPSS software. In those cases where the number of strains exceeded 3, the paired-sample Wilcoxon signed-rank test was employed to identify significant differences. In each case, at t ϭ 6 h and t ϭ 24 h differences were calculated. A P value of Ͻ0.05 was considered to be significant. Table 1 shows the MIC values for the tested B. fragilis strains for the respective antimicrobial agent and the breakpoints according to EUCAST (6) . The investigated strains were divided by a cutoff at 8.0 g/ml into two groups: the susceptible/wild-type group and the resistant group, respectively. For clindamycin, the same cutoff is used independently of the breakpoint (4 g/ml) according to EUCAST (6) . The chosen cutoff at 8.0 g/ml also separates two different groups, the wild-type and the resistant groups.
The pooled kill kinetic curves for B. fragilis strains with MICs of Յ8.0 g/ml are shown in Fig. 1 . At concentrations above the MIC, clindamycin showed bactericidal activity against only 5 out of 10 strains. Imipenem was bactericidal against 8 out of 9 strains, and metronidazole was bactericidal against 10 out of 10 strains. Piperacillin-tazobactam showed bactericidal activity against 6 out of 8 strains investigated. Piperacillin-tazobactam was the only antibiotic regime in which statistically significant differences were found after 6 h of incubation. The use of 4ϫ MIC resulted in a higher killing rate than the use of 1ϫ MIC (P Ͻ 0.05). A significantly higher killing rate using 1ϫ MIC or 4ϫ MIC instead of 0.5ϫ MIC and clindamycin or imipenem, respectively, occurred at t ϭ 24 h (P Ͻ 0.05). Between 1ϫ MIC and 4ϫ MIC, no statistical significances were found for clindamycin or imipenem, respectively. In contrast, increasing concentrations of metronidazole or piperacillin-tazobactam resulted in significantly higher killing rates after 24 h (P Ͻ 0.05).
The pooled kill kinetic curves for B. fragilis strains with MIC values of Ͼ8.0 g/ml are shown in Fig. 2 . The two metronidazoleresistant strains were effectively killed by metronidazole when concentrations of C max (16 g/ml) or more were used. Also, two of three imipenem-resistant strains were killed by imipenem with concentrations of C max (32 g/ml) or more. Piperacillin-tazobactam showed activity against 3 of the 4 piperacillin-tazobactamresistant strains when concentrations of C max (piperacillin, 60 g/ ml, and tazobactam, 25 g/ml) or higher were used. In contrast, clindamycin did not inhibit the bacterial growth of the clindamycin-resistant strains even at concentrations of 4ϫ C max (64 g/ ml). Due to the limited number of strains with MICs of Ͼ8 g/ml, statistical analysis could be performed only for piperacillin-tazo- bactam. However, no statistical differences in killing rates could be found even between 0.5ϫ C max and 4ϫ C max .
Comparing the prior established MICs by Etest with the assessed kill kinetics, a good correlation could be found when the organisms were susceptible to the respective antibiotic agent. Furthermore, in the present study imipenem showed a slightly better effect than did piperacillin-tazobactam. In contrast, clinical trials comparing piperacillin-tazobactam with imipenem/cilastatin in patients with intra-abdominal infections revealed equal efficacy (5, 18) or slight advantages for piperacillin-tazobactam (4). Against resistant strains, clindamycin showed no effect on those strains while metronidazole could show a rather good effect. Thus, metronidazole appeared to be the most effective investigated substance but still needs to be combined with another antibiotic to cover infections with aerobic bacteria in mixed infections.
In summary, the kill kinetics over time could provide additional information on local resistance patterns, which is of utmost importance for an adequate prophylaxis and treatment in anaerobic or mixed infections. Kill kinetics assays should be performed in studies after establishing MIC values and also choosing resistant strains.
